Xenetic Biosciences (XBIO) Company Report

Xenetic Biosciences, Inc. reported a net loss of approximately $0.5 million for the third quarter ended September 30, 2025, while revenue increased by approximately $0.4 million, or 67.2%, to approximately $1.0 million compared to the same period in 2024.
The company ended the quarter with approximately $4.1 million in cash and subsequently secured net proceeds of approximately $3.9 million from an October 2025 offering, which is expected to extend its cash runway.
Research & development expenses for Q3 2025 increased by approximately $0.4 million, or 105.6%, to approximately $0.8 million, primarily due to increased manufacturing development efforts and pre-clinical research.
Xenetic is advancing its DNase-based technology towards Phase 1 clinical development for pancreatic carcinoma and other solid tumors, building on completed preclinical proof-of-concept studies.

Nov 13, 2025, 1:45 PM

Xenetic Biosciences, Inc. announces pricing of common stock offering

XBIO

Xenetic Biosciences, Inc. priced an underwritten offering of 735,000 shares of common stock at $6.12 per share on October 10, 2025.
The offering is expected to generate approximately $4.5 million in gross proceeds and $3.9 million in net proceeds.
The company intends to use the net proceeds for working capital, general corporate purposes, and the advancement of its DNase technology.
The offering is expected to close on or about October 14, 2025.
Canaccord Genuity LLC is acting as the sole bookrunner for the offering.